Value Plus

Arihant's Value Plus - June 2017

Market Outlook June: Going ahead, the Indian economy will strengthen as the government pushing through several key reforms such as liberalisation of FDI rules in key sectors, July rollout of the Goods & Service Tax (GST) and a national bankruptcy code which will improve growth in long term. Further, expectations of good monsoon, banking sector reforms, RBI monetary policy which will be scheduled on 7th Jun, 2017 are the major factors which will be keenly watched by investors. On the global front, the US FOMC meeting, European Central Bank (ECB) monetary policy, Japanese monetary policy and BoE Monetary Policy will be keenly watched by market participants. Hence, we recommend investors to invest in good companies with long term horizon.

In this issue:

  • Movers & Shakers
  • Market Outlook
  • Nifty Technical Outlook
  • Technical Picks
  • Auto Sales
  • Commodity Outlook
  • Mutual Fund
  • Key Financial Events – June

Nifty Technical Outlook June: On the monthly chart, we are observing a bull candle which clearly reflects that momentum on the upside is likely to continue. In the coming month if Nifty trades and closes above 9696 level then it is likely to test 9807 – 9918 – 10047 levels. However, if Nifty trades and closes below 9545 level then it can test 9435 – 9324 – 9195 levels.

Broadly, we are of the opinion that as long as Nifty holds 9435 there is high probability that Nifty may test the 9800 – 9900 in couple of months.

Tags: Technical StocksAuto SalesKey EventsMutual FundMovers & ShakersCommodity OutlookMarket OutlookNifty Technical Outlook

Arihant's June Investment Newsletter is now available #‎ValuePlus
Click here to go through our flipbook now.
Click here to download full pdf report.

Search Reports



Daily Metal & Agro Buzz

HIGHLIGHTS: Natural gas...

Read More

Daily Market Update...

On 22/03/2018 markets opened...

Read More

Daily Metal & Agro Buzz:

HIGHLIGHTS: Cane arrears of...

Read More

Daily Currency Market...

HIGHLIGHTS: The dollar fell...

Read More

Daily Market Update...

On 21/03/2018 markets opened...

Read More



Read More



Read More

Century Textile

We have valued each segment...

Read More



Read More

Ajanta Pharma Initiating...

Ajanta Pharma (AJP) delivered...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions.